Addex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program
December 20, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, December 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Indivior PLC (LON: INDV)...
ADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES
December 18, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 18 December 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it...
Addex: Van Leeuwenhoeck Issues Update Equity Research Report
December 03, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, December 3, 2019 – Addex Therapeutics (SIX: ADXN), a clinical-stage leading allosteric modulation-based drug discovery and development company, today announced the independent...
Addex to Attend Jefferies 2019 London Healthcare Conference
November 13, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 13, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer, Tim...
Addex to Attend BIO-Europe Conference in Hamburg
November 08, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer Tim...
Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program
October 08, 2019 01:00 ET
|
Addex Therapeutics
Indivior Investment Reflects Progress Towards Clinical Evaluation and Validates Power of Allosteric Platform Geneva, Switzerland, October 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading...
Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update
September 30, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 30, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today reported its half-year financial results...
ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019
September 25, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 25, 2019 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its half-year 2019...
Addex Therapeutics Submits Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Shares
September 24, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 24 September 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it...
Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target of CHF11-12 per Share
August 27, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 27, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that the independent life...